Goldman Sachs’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $128M | Buy |
1,699,847
+843,881
| +99% | +$66.6M | 0.01% | 893 |
|
|
2025
Q4 | $67.7M | Buy |
855,966
+78,396
| +10% | +$5.9M | 0.01% | 1251 |
|
|
2025
Q3 | $50.9M | Sell |
777,570
-370
| -0% | -$18.1K | 0.01% | 1403 |
|
|
2025
Q2 | $30.7M | Buy |
777,940
+125,422
| +19% | +$4.1M | ﹤0.01% | 1730 |
|
|
2025
Q1 | $19.7M | Buy |
652,518
+274,310
| +73% | +$8.98M | ﹤0.01% | 2047 |
|
|
2024
Q4 | $13.2M | Buy |
378,208
+142,498
| +60% | +$5.33M | ﹤0.01% | 2534 |
|
|
2024
Q3 | $9.44M | Sell |
235,710
-92,595
| -28% | -$4.31M | ﹤0.01% | 2791 |
|
|
2024
Q2 | $15.6M | Buy |
328,305
+127,925
| +64% | +$5.25M | ﹤0.01% | 2081 |
|
|
2024
Q1 | $8.69M | Sell |
200,380
-181,002
| -47% | -$8.63M | ﹤0.01% | 2597 |
|
|
2023
Q4 | $19.3M | Buy |
381,382
+43,555
| +13% | +$2.09M | ﹤0.01% | 1933 |
|
|
2023
Q3 | $15.3M | Buy |
337,827
+149,455
| +79% | +$6.17M | ﹤0.01% | 2017 |
|
|
2023
Q2 | $7.73M | Sell |
188,372
-233,726
| -55% | -$8.98M | ﹤0.01% | 2696 |
|
|
2023
Q1 | $15.1M | Sell |
422,098
-500,313
| -54% | -$18.8M | ﹤0.01% | 2055 |
|
|
2022
Q4 | $34.8M | Sell |
922,411
-368,154
| -29% | -$15.5M | 0.01% | 1463 |
|
|
2022
Q3 | $57.1M | Buy |
1,290,565
+248,741
| +24% | +$10.5M | 0.01% | 1021 |
|
|
2022
Q2 | $38.6M | Buy |
1,041,824
+87,498
| +9% | +$3.3M | 0.01% | 1315 |
|
|
2022
Q1 | $35.3M | Buy |
954,326
+365,028
| +62% | +$11.9M | 0.01% | 1595 |
|
|
2021
Q4 | $17.9M | Sell |
589,298
-12,538
| -2% | -$395K | ﹤0.01% | 2213 |
|
|
2021
Q3 | $20.2M | Sell |
601,836
-77,593
| -11% | -$2.92M | ﹤0.01% | 2054 |
|
|
2021
Q2 | $27.1M | Sell |
679,429
-65,481
| -9% | -$2.56M | 0.01% | 1783 |
|
|
2021
Q1 | $33.5M | Sell |
744,910
-299,144
| -29% | -$16.7M | 0.01% | 1484 |
|
|
2020
Q4 | $59M | Buy |
1,044,054
+453,994
| +77% | +$22.6M | 0.02% | 993 |
|
|
2020
Q3 | $28M | Sell |
590,060
-173,718
| -23% | -$9.65M | 0.01% | 1470 |
|
|
2020
Q2 | $45M | Buy |
763,778
+44,028
| +6% | +$2.45M | 0.01% | 1033 |
|
|
2020
Q1 | $34M | Buy |
719,750
+184,724
| +35% | +$10.3M | 0.01% | 1125 |
|
|
2019
Q4 | $32.3M | Sell |
535,026
-35,203
| -6% | -$2.1M | 0.01% | 1476 |
|
|
2019
Q3 | $34.2M | Sell |
570,229
-918,846
| -62% | -$59.9M | 0.01% | 1371 |
|
|
2019
Q2 | $95.7M | Buy |
1,489,075
+997,199
| +203% | +$70.5M | 0.03% | 700 |
|
|
2019
Q1 | $39.9M | Sell |
491,876
-693,876
| -59% | -$44.8M | 0.01% | 1309 |
|
|
2018
Q4 | $64.1M | Sell |
1,185,752
-409,723
| -26% | -$20.9M | 0.02% | 900 |
|
|
2018
Q3 | $82.3M | Sell |
1,595,475
-69,548
| -4% | -$3.27M | 0.02% | 887 |
|
|
2018
Q2 | $69.4M | Sell |
1,665,023
-290,944
| -15% | -$12.9M | 0.02% | 986 |
|
|
2018
Q1 | $86.2M | Buy |
1,955,967
+27,069
| +1% | +$1.38M | 0.02% | 866 |
|
|
2017
Q4 | $97M | Buy |
1,928,898
+242,041
| +14% | +$13.3M | 0.02% | 809 |
|
|
2017
Q3 | $85.5M | Buy |
1,686,857
+221,721
| +15% | +$11.6M | 0.02% | 904 |
|
|
2017
Q2 | $74.5M | Buy |
1,465,136
+728,147
| +99% | +$33.9M | 0.02% | 981 |
|
|
2017
Q1 | $29.6M | Buy |
736,989
+44,372
| +6% | +$1.99M | 0.01% | 1602 |
|
|
2016
Q4 | $33.1M | Sell |
692,617
-367,521
| -35% | -$14.5M | 0.01% | 1576 |
|
|
2016
Q3 | $38.8M | Buy |
1,060,138
+53,132
| +5% | +$1.66M | 0.01% | 1392 |
|
|
2016
Q2 | $23.5M | Buy |
1,007,006
+329,683
| +49% | +$10.6M | 0.01% | 1682 |
|
|
2016
Q1 | $27.4M | Sell |
677,323
-719,909
| -52% | -$29.2M | 0.01% | 1489 |
|
|
2015
Q4 | $86.5M | Buy |
1,397,232
+262,275
| +23% | +$14.2M | 0.03% | 744 |
|
|
2015
Q3 | $45.9M | Buy |
1,134,957
+193,475
| +21% | +$10M | 0.02% | 1116 |
|
|
2015
Q2 | $54.2M | Sell |
941,482
-166,715
| -15% | -$10.6M | 0.02% | 1062 |
|
|
2015
Q1 | $70.6M | Buy |
1,108,197
+658,798
| +147% | +$44.7M | 0.02% | 840 |
|
|
2014
Q4 | $27.7M | Sell |
449,399
-326,906
| -42% | -$16.1M | 0.01% | 1580 |
|
|
2014
Q3 | $30.1M | Sell |
776,305
-273
| -0% | -$9.68K | 0.01% | 1475 |
|
|
2014
Q2 | $26.8M | Buy |
776,578
+212,583
| +38% | +$6.69M | 0.01% | 1564 |
|
|
2014
Q1 | $24.4M | Sell |
563,995
-24,394
| -4% | -$1.18M | 0.01% | 1607 |
|
|
2013
Q4 | $23.4M | Buy |
588,389
+60,587
| +11% | +$2.16M | 0.01% | 1617 |
|
|
2013
Q3 | $19.8M | Buy |
527,802
+90,102
| +21% | +$2.69M | 0.01% | 1635 |
|
|
2013
Q2 | $11.8M | Buy |
+437,700
| New | +$9.31M | ﹤0.01% | 1954 |
|
Other funds holding IONS
VPM
VCM
Goldman Sachs's IONS Position: Q1 2026 in Review
Goldman Sachs increased its Ionis Pharmaceuticals (IONS) stake by 99% in Q1 2026, buying an estimated $66.6M and bringing the position to 1,699,847 shares worth $128M. The position accounts for 0.01% of the portfolio, ranked #893.
Goldman Sachs first reported a position in IONS in Q2 2013 and has held it in 52 quarters since. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.
- Goldman Sachs held 1,699,847 shares of Ionis Pharmaceuticals worth $128M as of Q1 2026.
- Goldman Sachs bought 843,881 Ionis Pharmaceuticals shares in Q1 2026, an estimated $66.6M.
- Ionis Pharmaceuticals made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #893 holding.
- Goldman Sachs first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.